More intense bladder cancer treatment does not improve survival, U-M study findsApril 08, 2009ANN ARBOR, Mich. - Despite enduring more invasive tests and medical procedures, patients who were treated aggressively for early stage bladder cancer had no better survival than patients who were treated less aggressively. Further, the aggressively treated patients were more likely to undergo major surgery to have their bladder removed, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. Because bladder cancer is often treated as a chronic disease requiring lifelong surveillance, it is among the most expensive cancers to treat in the United States. Urologists vary widely in how they approach early stage, or non-muscle-invasive, bladder cancer. In this study, researchers gathered data from the Surveillance, Epidemiology and End Results Medicare database. They looked at 940 doctors who provided care to 20,713 early stage bladder cancer patients. Each doctor included in the study had treated at least 10 patients for bladder cancer. Results of the study appear in the April 15 issue of the Journal of the National Cancer Institute. The study found that average per-patient treatment expenditures ranged from $2,830 for doctors in the low-intensity treatment category to $7,131 for doctors in the high-intensity category. At the same time, survival rates across all intensity categories were similar. "What this indicates is that some doctors are providing potentially unnecessary care, or care without measurable benefit to the patient. It makes sense to many doctors and patients that more would be better, but unfortunately there can be unintended consequences of unneeded care," says study author Brent Hollenbeck, M.D., M.S., assistant professor of urology at the U-M Medical School. The study found that patients treated more aggressively had more imaging procedures and more invasive surgical procedures. The aggressively treated patients were also nearly twice as likely to require major medical interventions, and were 2.5 times more likely to undergo radical cystectomy, a procedure to remove the bladder. The study authors suggest that certain patients might still benefit from greater intensity of care, but further research is needed to determine which patients would benefit. Hollenbeck also urges randomized clinical trials to look at the value of some of the more expensive and common health services to determine their optimal use for patients with early stage bladder cancer. "Urologists should not assume that more aggressive management of early stage bladder cancer will translate into better outcomes for their patients. By reducing unnecessary health care, we can reduce wasteful spending, which will lessen the cost burden of bladder cancer, one of the most expensive cancers to treat from diagnosis to death," Hollenbeck says. University of Michigan Health System |
|||||||||||||||||||||
| Related Bladder Cancer Current Events and Bladder Cancer News Articles Prediction model superior to traditional criteria in bladder treatment decision A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. Hopkins scientists find cells responsible for bladder cancer's spread Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth. Variation in prostate stem cell antigen gene raises bladder cancer risk Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center. UT Southwestern researchers investigate high-risk populations for bladder-cancer screenings A new study by UT Southwestern Medical Center researchers sheds light on the challenges involved in identifying which high-risk population would benefit most from bladder-cancer screening. DKK-3 and WIF-1: Proteins related to liver cancer development? Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year. Certain ecologic factors associated with greater risk of bladder cancer Persons drinking well water (as opposed to public supply) may be at an increased risk of bladder cancer, according to new research from the University of Alabama at Birmingham. Researchers will present data about the relationship between bladder cancer and certain ecologic factors including water source and UV radiation levels at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence Making tumors inside the bladder fluoresce red under blue light allows physicians to more easily find and remove them, substantially reducing the rate at which these cancers come back, says a Mayo Clinic physician who is presenting results of a large, multicenter international clinical trial. Genetic Variants Predict Recurrence of Bladder Cancer, Patient Survival Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy. New Discovery Raises Doubts About Use of Certain Targeted Therapies in Bladder Cancer Researchers at the University of Virginia Health System have found that one of the genes commonly thought to promote the growth and spread of some types of cancers is in fact beneficial in bladder cancer - a major discovery that could significantly alter the way bladder cancers are treated in the future. New investigational treatment for bladder cancer, identified with Columbia-developed research model A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer. More Bladder Cancer Current Events and Bladder Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||